BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-864@pharmaconomics
DTSTAMP:20260707T033836Z
DTSTART;VALUE=DATE:20260101
DTEND;VALUE=DATE:20260102
SUMMARY:COGT AdCom — bezuclastinib
DESCRIPTION:An FDA advisory committee reviews bezuclastinib for GIST who have received prior treatment with imatinib around Jan 1\, 2026. The panel's public vote often front-runs the agency's final verdict — and the share price.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1622229/000119312526053131/cogt-ex99_1.htm\n\nTrack it: https://pharmaconomics.com/e/864
URL:https://pharmaconomics.com/e/864
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:COGT catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR